JW 133 is primarily used in research settings as a potent and selective agonist for the GPR119 receptor, which is involved in glucose homeostasis and insulin secretion. Its main application lies in the study of metabolic disorders, particularly type 2 diabetes. By activating GPR119, JW 133 stimulates the release of incretin hormones such as GLP-1, which enhances insulin production in a glucose-dependent manner, making it a valuable tool for investigating new antidiabetic therapies. It is also used to explore the role of GPR119 in appetite regulation and lipid metabolism, contributing to research on obesity and related conditions. Due to its high selectivity and potency, JW 133 serves as a reference compound in pharmacological assays and target validation studies.